Shanghai Kaibao Pharmaceutical

China

300039.CS▼3

Shanghai Kaibao first-half 2026 net profit 102 million yuan, down 16.42% year on year

Shanghai Kaibao disclosed its 2026 semi-annual report. In the first half, total operating revenue was 463 million yuan, down 23.44% year on year. Net profit attributable to the parent company was 102 million yuan, down 16.42% year on year. Net profit after deducting non-recurring items was 96.9969 million yuan, down 17.37% year on year. Net cash flow from operating activities was 109 million yuan, down 31.92% year on year. Basic earnings per share were 0.0975 yuan, and the weighted average return on equity was 2.32%. Based on the closing price on August 24, the company's price-to-earnings ratio on a trailing twelve-month basis was about 21.4 times, the price-to-book ratio on a latest fiscal year basis was about 1.29 times, and the price-to-sales ratio on a trailing twelve-month basis was about 5.47 times.

Shanghai Kaiba… ▼

300039.CS · Capital · Negative First-half net profit down 16.42% and revenue down 23.44% year on year.

Read original ↗

中国证券报·41dRead more →

300039.CS▲

State Council Approves Traditional Chinese Medicine 15th Five-Year Plan, Igniting TCM Sector; Longshen Rongfa Hits 20% Daily Limit Up

The State Council has approved in principle the Traditional Chinese Medicine Revitalization and Development 15th Five-Year Plan, igniting the TCM sector. On July 13, Longshen Rongfa hit the 20 percent daily limit up, Shanghai Kaibao and Biotech Valley surged over 10 percent, Tianmu Pharmaceutical hit the daily limit up, and many other stocks rose in sympathy. CITIC Securities believes that the cliff-like drop in upstream precious medicinal material prices has shed the cost burden, the midstream destocking cycle is nearing its end, and cost savings will flow through to the income statement. The current moment is the optimal window for contrarian positioning in the profit recovery inflection point of the TCM OTC sector. China Post Securities noted that branded TCM companies have stable cash flows, and high-dividend TCM firms are trading at historically reasonable or low valuations, offering allocation appeal in a low-interest-rate environment. It suggests paying attention to names such as Dong-E-E-Jiao, Jumpcan Pharmaceutical, and China Resources Jiangzhong.

Gansu Longshen… ▲Shan Dong Dong… ▲Hubei Jumpcan… ▲Jiangzhong Pha… ▲Shanghai Kaiba… ▲Hangzhou TianM… ▲

300534.CS · Regulation · Positive State Council approval of TCM 15th Five-Year Plan directly benefits Longshen Rongfa as a TCM company, driving its 20% limit-up.

云南生物谷药业股份有限公司 (Yunnan Biovalley Pharmaceutical Co., Ltd.) · Regulation · Positive State Council approval of TCM 15th Five-Year Plan boosts Biotech Valley, a TCM firm, leading to over 10% surge.

000423.CS · Demand · Positive Dong-E-E-Jiao mentioned by analyst as a high-dividend TCM firm with allocation appeal in low-rate environment.

600566.CG · Demand · Positive State Council approval of TCM 15th Five-Year Plan boosts sector demand; analyst notes high-dividend TCM firms like Jumpcan have allocation appeal.

600750.CG · Demand · Positive China Resources Jiangzhong mentioned by analyst as a high-dividend TCM firm with allocation appeal in low-rate environment.

300039.CS · Demand · Positive Shanghai Kaibao surged over 10% on sector rally driven by State Council plan approval.

Read original ↗

21世纪经济·84dRead more →